natgillin/translations-raw huggingface dataset:
In one study involving 123 children aged 6 to 16 years, Zebinix over 12 weeks halved the number of seizures in 51% of patients (42 out of 83).
V eni študiji, ki je vključevala 123 otrok, starih med šest in 16 let, se je število napadov v 12 tednih zdravljenja z zdravilom Zebinix zmanjšalo za polovico pri 51-% (42 od 83) bolnikov.
For adults, the most common side effects with Zebinix (seen in more than 1 patient in 10) are dizziness, somnolence (sleepiness), headache and nausea.
Najpogostejši neželeni učinki zdravila Zebinix pri odraslih (opaženi pri več kot 1 bolniku od 10) so omotica, somnolenca (zaspanost), glavobol in navzeja.
Zebinix received a marketing authorisation valid throughout the EU on 21 April 2009.
Evropska komisija je dovoljenje za promet z zdravilom Zebinix, veljavno po vsej Evropski uniji, izdala 21.-aprila-2009.
The European Medicines Agency decided that Zebinix's benefits are greater than its risks and that it be authorised for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Zebinix večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
What are the risks associated with Zebinix?
Kakšna tveganja so povezana z zdravilom Zebinix?
What benefit of Zebinix have been shown in studies?
Kakšne koristi je zdravilo Zebinix izkazalo v študijah?
What is Zebinix and what is it used for?
Kaj je zdravilo Zebinix in za kaj se uporablja?
Zebinix is an epilepsy medicine used to treat adults with partial-onset seizures (epileptic fits) with or without secondary generalisation.
Zdravilo Zebinix je zdravilo proti epilepsiji, ki se uporablja za zdravljenje odraslih, ki imajo napade parcialnega izvora (epileptične napade) s sekundarno generalizacijo ali brez nje.
Zebinix should not be used in patients with severe kidney problems and the dose should be adjusted in moderately impaired kidney function.
Zdravila Zebinix ne smejo jemati bolniki s hudimi težavami z ledvicami, pri zmerni okvari delovanja ledvic pa je treba odmerek prilagoditi.
Another study compared Zebinix taken on its own with another epilepsy medicine, carbamazepine, in 815 newly diagnosed adults.
V drugi študiji so primerjali samostojno jemanje zdravila Zebinix z drugim zdravilom proti epilepsiji, karbamazepinom, pri 815 odraslih z novoodkrito boleznijo.
The active substance in Zebinix, eslicarbazepine acetate, is converted into eslicarbazepine in the body.
Zdravilna učinkovina v zdravilu Zebinix, eslikarbazepin acetat, se v telesu pretvori v eslikarbazepin.
Zebinix can be taken on its own, in newly diagnosed epilepsy, or can be added to existing antiepileptic medicines.
Zdravilo Zebinix se lahko jemlje samostojno pri novoodkriti epilepsiji ali se ga doda že uporabljanim zdravilom proti epilepsiji.
Over the 12 weeks of treatment, this fell to 9.8 and 9.0 seizures per month in patients taking Zebinix 800 mg and Zebinix 1,200 mg respectively, compared with 11.7 per month in those taking placebo.
V 12 tednih zdravljenja se je število napadov zmanjšalo na 9,8 napadov mesečno pri bolnikih, ki so jemali zdravilo Zebinix 800-mg, oziroma na 9,0 napadov mesečno pri bolnikih, ki so jemali zdravilo Zebinix 1-200-mg, v primerjavi z 11,7 napada mesečno pri bolnikih, ki so jemali placebo.
Looking at the results of the three studies taken together, Zebinix 800 mg and 1,200 mg were more effective than placebo at reducing the number of seizures, when used as add-on to other epilepsy medicines.
Upoštevajoč rezultate vseh treh študij skupaj sta bila 800-miligramski in 1 200-miligramski odmerek zdravila Zebinix, uporabljena kot dodatek k drugim zdravilom proti epilepsiji, učinkovitejša od placeba pri zmanjševanju števila napadov.
For adults who take Zebinix on its own, a dose up to 1,600 mg may be used.
Odrasli, ki jemljejo zdravilo Zebinix samostojno, lahko uporabijo odmerek do 1-600-mg.
Why is Zebinix authorised?
Zakaj je bilo zdravilo Zebinix odobreno?
Three main studies compared Zebinix with placebo (a dummy treatment) in 1,050 adults with partialonset seizures that were not controlled by other medicines.
V treh glavnih študijah so učinke zdravila Zebinix primerjali s placebom (zdravilom brez zdravilne učinkovine) pri 1-050 odraslih z napadi parcialnega izvora, za obvladovanje katerih niso uporabljali drugih zdravil.
For more information about using Zebinix, see the package leaflet or contact your doctor or pharmacist.
Za praktične informacije o uporabi zdravila Zebinix naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
For children and adults who use Zebinix in combination with other medicines the maximum dose is 1,200 mg once a day.
Odrasli in otroci, ki jemljejo zdravilo Zebinix v kombinaciji z drugimi zdravili je na maksimalni odmerek 1-200-mg.
For adults and children weighing 60 kg or more, treatment is started at a dose of 400 mg once a day, before increasing it to the standard dose of 800 mg once a day after one or two weeks.
Zdravljenje z zdravilom Zebinix se pri odraslih in otrocih, ki so težji od 60 kg, začne s 400miligramskim odmerkom enkrat dnevno, ki se nato po enem ali dveh tednih poveča na standardni odmerek 800-mg enkrat dnevno.
Zebinix contains the active substance eslicarbazepine acetate.
Zdravilo Zebinix vsebuje zdravilno učinkovino eslikarbazepin acetat.
The dose is then increased after one or two weeks to 20 mg/kg per day and then to 30 mg/kg per day, based on the patient's response.
Pri otrocih, ki tehtajo manj kot 60 kg, znaša začetni odmerek 10 mg na kg telesne mase enkrat na dan. Odmerek se nato po enem ali dveh tednih poveča na 20 mg/kg na dan in nato na 30 mg/kg na dan, odvisno od bolnikovega odziva.
How does Zebinix work?
Kako zdravilo Zebinix deluje?
Zebinix can only be obtained with a prescription.
Predpisovanje in izdaja zdravila Zebinix je le na recept.
For the full list of side effects and restrictions with Zebinix, see the package leaflet.
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Zebinix, glejte navodilo za uporabo.
How is Zebinix used?
Kako se zdravilo Zebinix uporablja?
Zebinix (eslicarbazepine acetate)
Zebinix eslikarbazepin acetat
This information supplements the sections 3 and 5 for the user.
Te informacije dopolnjujejo poglavji 3 in 5, namenjeni uporabniku.
Not known (frequency cannot be estimated from the available data)
Neznani (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov)
Date of first authorisation: 01 February 2013 Date of latest renewal: 21 September 2017
Datum prve odobritve: 01 februar 2013 Datum zadnjega podaljšanja: 21 september 2017
These effects were fully reversible within 8-18 weeks after the last injection.
Ti učinki so bili povsem reverzibilni v 8 do 18 tednih po zadnji injekciji.
These animals also lost normal menstrual cycling.
Te živali so tudi izgubile normalne menstruacijske cikluse.
Invasive dental procedures are also an identified risk factor.
Invazivni zobozdravstveni postopki so prav tako opredeljeni dejavnik tveganja.
Your doctor should monitor you carefully.
Vaš zdravnik vas mora skrbno nadzirati.
As determined per IVRS
a Določeno z IVRS
The infusion sets should be made of one of the following materials:
Kompleti za infundiranje naj bodo izdelani iz enega od naslednjih materialov:
This is considered as one treatment cycle.
To velja kot en ciklus zdravljenja.
Sometimes, depending on where this happens, you may get an unusual discharge at that place.
Včasih se vam lahko - odvisno od tega, kje se to zgodi - pojavi nenavaden izcedek na tistem mestu.
• You will usually be given an infusion once every 2 weeks.
• Po navadi boste dobili po eno infuzijo enkrat na 2 tedna.
• in your eye, since it may severely damage it.
• v oko, saj ga lahko hudo poškoduje.
You may need to go to the hospital for treatment.
Morda boste morali na zdravljenje v bolnišnico.
• for at least 6 months after the last dose of treatment.
• vsaj še 6 mesecev po zadnjem odmerku tega zdravila.
• changes in the colour of the skin.
• spremembe barve kože.
Please also read the package leaflets for the other medicines (‘chemotherapy') that are part of your treatment, to see if they are suitable for you.
Preberite tudi navodila za uporabo drugih zdravil ("kemoterapija"), ki so del vašega zdravljenja, da boste videli, ali so primerna za vas.
Hypertension may exacerbate underlying cardiovascular disease.
Hipertenzija lahko poslabša osnovne kardiovaskularne bolezni.
From a microbiological point of view, the solution for infusion should be used immediately.
Z mikrobiološkega stališča je treba raztopino za infundiranje uporabiti takoj.
You may need to read it again, or provide it to future healthcare providers.
Morda ga boste želeli ponovno prebrati, ali ga izročiti svojim prihodnjim zdravnikom.
• feeling tired or weak
• občutek utrujenosti ali šibkosti
The treatment cycle is repeated every 2 weeks.
Ciklus zdravljenja se ponavlja vsaka 2 tedna.
The primary efficacy endpoint was overall survival.
Primarni opazovani dogodek učinkovitosti je bilo celokupno preživetje.
• your level of everyday activities is limited or worsens on treatment.
• če je vaša raven vsakodnevnih dejavnosti omejena ali se med zdravljenjem poslabša.
Men and women who can father or have children should use effective contraception:
Moški in ženske, ki bi lahko zaplodili in imeli otroke, morajo uporabljati učinkovito kontracepcijo:
• Your doctor will decide how often you will be given the medicine and if you need a change in the dose.
• Zdravnik bo presodil, kako pogosto boste dobivali zdravilo in ali potrebujete spremembo odmerka.
Unopened vial 3 years
Neodprta viala 3 leta
Your doctor will decide the appropriate doses for these other chemotherapy medicines.
Vaš zdravnik vam bo določil ustrezne odmerke teh drugih zdravil za kemoterapijo.
This medicine is not for children or adolescents under the age of 18 years because the safety and benefit of using ZALTRAP in children and adolescents have not been shown.
To zdravilo ni primerno za otroke ali mladostnike, stare manj kot 18 let, saj varnost in korist zdravljenja z zdravilom ZALTRAP pri otrocih in mladostnikih nista dokazani.
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products or solvents except those mentioned in section 6.6.
Zaradi pomanjkanja študij kompatibilnosti se tega zdravila ne sme mešati z drugimi zdravili ali vehikli razen s tistimi, ki so navedeni v poglavju 6.6.
It is therefore also important to tell your doctor, pharmacist or nurse if you have other heart problems since high blood pressure could make these worse.
Pomembno je tudi, da svojemu zdravniku, farmacevtu ali medicinski sestri poveste, če imate kakšne druge težave s srcem, kajti visok krvni tlak lahko to poslabša.
If you are a woman that could become pregnant you should use effective contraception (see “Contraception” section below for details on male and female contraception).
Če ste ženska, ki bi lahko zanosila, morate uporabljati učinkovito kontracepcijo (za podrobnosti o kontracepciji pri moških in ženskah glejte spodnje poglavje “Kontracepcija” ).
• The drip (infusion) lasts for about 1 hour.
• Kapalna (infuzija) traja približno 1 uro.
Frequency Category
Kategorija pogostnosti
Signs may include dizziness especially when going from sitting to standing.
Med znaki je lahko omotica, zlasti pri vstajanju iz sedečega v stoječ položaj.
During treatment, your doctor will perform a number of tests to monitor the function of your body and how the medicine is working.
Med zdravljenjem bo vaš zdravnik izvajal številne preiskave, s katerimi bo kontroliral delovanje vašega telesa in delovanje zdravila.
How much and how often you will receive treatment
Koliko zdravila boste dobivali in kako pogosto
They may also prescribe a medicine called ‘G-CSF' to help prevent complications if your white blood cell count is too low.
Predpiše vam lahko tudi zdravilo, imenovano "G-CSF", ki pomaga preprečiti zaplete, če se število belih krvnih celic preveč zmanjša.
Immunogenicity data are highly dependent on the sensitivity and specificity of the assay.
Podatki o imunogenosti so izredno odvisni od senzitivnosti in specifičnosti preskusa.
Paediatric population The safety in paediatric patients has not been established.
Pediatrična populacija Varnost pri pediatričnih bolnikih ni ugotovljena.
Cases of overdose should be managed by appropriate supportive measures particularly with regard to monitoring and treatment of hypertension and proteinuria.
Primere prevelikega odmerjanja je treba obravnavati z ustreznimi podpornimi ukrepi, zlasti kar zadeva spremljanje in zdravljenje hipertenzije in proteinurije.
• during treatment with ZALTRAP and
• med zdravljenjem z zdravilom ZALTRAP in
Any unused concentrate should be discarded.
Ves neporabljeni koncentrat je treba zavreči.
Other sources of information
Drug vir informacij
Do not use ZALTRAP: • if you are allergic to aflibercept or any of the other ingredients of this medicine (listed in section
Ne uporabljajte zdravila ZALTRAP: • če ste alergični na aflibercept ali katero koli drugo sestavino tega zdravila (navedeno v poglavju
• haemorrhoids, bleeding or pain in the back passage
• hemoroidi, krvavitev ali bolečine v zadnjiku
This is because ZALTRAP may increase the risk of bleeding.
Zdravilo ZALTRAP namreč lahko poveča tveganje za krvavitve.
Frequencies are based on all grades and defined as: very common (≥ 1/10), common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
Pogostnosti temeljijo na vseh stopnjah in so opredeljene kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznano (ni mogoče oceniti iz razpoložljivih podatkov).
The use of granulocyte colony-stimulating factor (G-CSF) may be considered.
V poštev pride uporaba granulocitne kolonije stimulirajočega faktorja (G-CSF).
You should not use ZALTRAP during pregnancy unless you and your doctor decide that the benefit for you is greater than any possible risk to you or your unborn baby.
Zdravila ZALTRAP med nosečnostjo ne smete uporabljati, razen če skupaj s svojim zdravnikom presodite, da je korist za vas večja od možnega tveganja za vašega nerojenega otroka.
The concentrate solution must be clear and without particles.
Koncentrat za raztopino mora biti bister in brez delcev.
If you wear dentures you should make sure these fit properly.
Če nosite protezo, se morate prepričati, da se vam dobro prilega.
Filters made of polyvinylidene fluoride (PVDF) or nylon must not be used.
Ne sme se uporabljati filtrov, izdelanih iz polivinilidenfluorida (PVDF) ali najlona.
What ZALTRAP is and how it works
Kaj je zdravilo ZALTRAP in kako deluje
• The recommended dose is 4 mg for each kilogram of your body weight.
• Priporočeni odmerek je 4 mg na kilogram telesne mase.
Patients with thromboembolic events of Grade 3 or lower need to be closely monitored.
Bolnike z trombemboličnimi dogodki 3. ali nižje stopnje je treba skrbno spremljati.
PlGF and VEGF-B bind only to VEGFR-1, which is also present on the surface of leucocytes.
PlGF in VEGF-B se vežeta le na VEGFR-1, ki je prisoten tudi na površini levkocitov.
No studies have been conducted to assess the impact of ZALTRAP on milk production, its presence in breast milk or its effects on the breast-fed child.
Študij za oceno vpliva zdravila ZALTRAP na nastajanje mleka, njegove prisotnosti v materinem mleku in njegovih vplivov na dojenega otroka niso izvedli.
Table 4 - Post-hoc analyses excluding adjuvant patients a,b
Preglednica 4 - Post hoc analize (izključujoč adjuvantno zdravljene bolnike)a,b
Before initiating ZALTRAP, this risk should be carefully considered in patients with risk factors such as hypertension or history of aneurysm.
Pred uvedbo zdravila ZALTRAP je treba to tveganje skrbno preučiti pri bolnikih z dejavniki tveganja, kot sta hipertenzija ali anamneza anevrizme.
Animal toxicology and pharmacology
Živalska toksikologija in farmakologija
This may include medicines obtained without a prescription or herbal medicines.
To lahko velja tudi za zdravila, ki ste jih dobili brez recepta, in za zeliščna zdravila.
• Compromised wound healing requiring medical intervention
• slabšega celjenja ran, ki zahteva zdravniško ukrepanje
Intensity of the adverse reactions is graded according to NCI CTC version 3.0 (grade ≥ 3 = G ≥ 3).
Izrazitost neželenih učinkov je ocenjena po NCI CTC verzija 3.0 (stopnja ≥ 3 = S≥3).
ZALTRAP must not be injected into the eye, since it may severely damage it.
Zdravila ZALTRAP se ne sme injicirati v oko, saj ga lahko hudo poškoduje.
Pack size of 1 vial or 3 vials.
Pakiranje z 1 vialo ali 3 vialami.
If you are unsure, ask your doctor, pharmacist or nurse if there are any reasons why you cannot use these medicines.
Če ste negotovi, vprašajte zdravnika, farmacevta ali medicinsko sestro ali obstajajo kakšni razlogi, zaradi katerih ne bi smeli dobivati teh zdravil.
Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C to 8°C and for 8 hours at 25°C.
Kemična in fizikalna stabilnost med uporabo sta dokazani za 24 ur pri temperaturi od 2 do 8 °C in 8 ur pri temperaturi do 25 °C.
These data are exploratory and the statistical interaction test was non-significant (lack of evidence for heterogeneity in treatment effect between the RAS wild-type and RAS mutant subgroups).
Ti podatki so eksplorativni in statistični test za interakcijo ni bil značilen (pomanjkanje dokazov o heterogenosti terapevtskega učinka med podskupino z divjim tipom RAS in podskupino z mutantnim RAS).
• inflammation inside the nose and upper part of the throat
• vnetje v nosu in zgornjem delu žrela
It is important that you read the entire content of this procedure prior to the preparation of infusion solution.
Pomembno je, da pred pripravo raztopine za infundiranje preberete celoten opis tega postopka.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ZALTRAP therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba bodisi za prenehanje dojenja bodisi za prekinitev/prenehanje zdravljenja z zdravilom ZALTRAP, upoštevaje korist dojenja za otroka in korist zdravljenja za žensko.
Linear clearance observed in the dose range of 2 to 9 mg/kg is likely due to non saturable biological mechanisms of elimination such as protein catabolism.
Linearni očistek, opažen v razponu odmerkov od 2 do 9 mg/kg, je verjetno posledica nesaturabilnih bioloških mehanizmov odstranjevanja, npr. katabolizma beljakovin.
There is no information on the safety of aflibercept given at doses exceeding 7 mg/kg every 2 weeks or 9 mg/kg every 3 weeks.
Informacij o varnosti aflibercepta, uporabljenega v odmerkih, večjih od 7 mg/kg vsaka 2 tedna ali 9 mg/kg vsake 3 tedne, ni.
These were comparable between groups, and the difference between groups did not exceed ≥ 2 % incidence for the ZALTRAP/FOLFIRI regimen.
Med skupinama so bili primerljivi in razlika med skupinama ni presegla ≥ 2 % incidence s shemo ZALTRAP/FOLFIRI.
Grades ≥3
Stopnje ≥ 3
Treatment will continue as long as your doctor thinks the treatment is of benefit to you, and the side effects are acceptable.
Vaše zdravljenje se bo nadaljevalo, dokler zdravnik meni, da vam zdravilo koristi in dokler so neželeni učinki sprejemljivi.
Excessive activation of these receptors by VEGF-A can result in pathological neovascularisation and excessive vascular permeability.
Prekomerna aktivacija teh receptorjev z VEGF-A lahko povzroči patološko neovaskularizacijo in prekomerno permeabilnost žil.
Women of childbearing potential and fertile males should use effective contraception during and up to a minimum of 6 months after the last dose of treatment.
Ženske v rodni dobi in plodni moški morajo uporabljati učinkovito kontracepcijo med zdravljenjem in še najmanj 6 mesecev po zadnjem odmerku zdravila.
Tests may include blood and urine tests, x-ray or other scanning techniques and/or other tests.
Med takšnimi preiskavami so lahko preiskave krvi in urina, rentgensko slikanje ali druge tehnike slikanj in/ali druge preiskave.
The infusion should be temporarily suspended until the reaction resolves.
Infundiranje je treba začasno prekiniti, dokler reakcija ne mine.
Inform your doctor about your dental treatment and tell your dentist that you are being treated with ZALTRAP.
Obvestite svojega zdravnika o zdravljenju zob in povejte svojemu zobozdravniku, da se zdravite z zdravilom ZALTRAP.
• Hypertension that is not adequately controlled with anti-hypertensive therapy or occurrence of hypertensive crisis or hypertensive encephalopathy
• hipertenzije, ki ni ustrezno urejena z antihipertenzivnimi zdravili, pojava hipertenzivne krize ali hipertenzivne encefalopatije
There are no data from the use of aflibercept in pregnant women.
Podatkov o uporabi aflibercepta pri nosečnicah ni.
• PVC containing DEHP infusion bags or polyolefin infusion bags should be used.
• Uporabiti je treba infuzijske vrečke iz PVC, ki vsebuje DEHP, ali infuzijske vrečke iz poliolefina.
Aflibercept increased blood pressure in normotensive rodents.
Aflibercept je zvišal krvni tlak pri normotenzivnih glodalcih.
The European Medicines Agency has waived the obligation to conduct studies with ZALTRAP in all subsets of the paediatric population in adenocarcinoma of the colon and rectum (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je odstopila od obveze za izvedbo študij z zdravilom ZALTRAP za vse skupine pediatrične populacije pri adenokarcinomu kolona in rektuma (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Vascular endothelial growth factor A and B (VEGF-A, VEGF-B), and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as potent mitogenic, chemotactic, and vascular permeability factors for endothelial cells.
Žilna endotelijska rastna faktorja A in B (VEGF-A,-B VEGF) ter placentni rastni faktor (PlGF) spadajo v družino angiogenih faktorjev VEGF, ki lahko delujejo kot močni mitogeni, kemotaktični in žilni permeabilnostni faktorji za endotelijske celice.
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
Preden začnete dobivati zdravilo, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
There is no relevant use of ZALTRAP in the paediatric population for the indication of metastatic colorectal cancer.
Zdravilo ZALTRAP v pediatrični populaciji nima relevantne uporabe pri indikaciji metastatskega kolorektalnega raka.
Your doctor may need to treat the allergic reaction or stop your treatment with ZALTRAP.
Zdravnik bo morda moral zdraviti alergijsko reakcijo ali prekiniti vaše zdravljenje z zdravilom ZALTRAP.
VEGF-A acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells.
VEGF-A deluje preko dveh receptorskih tirozin-kinaz, VEGFR-1 in VEGFR-2, ki sta prisotni na površini endotelijskih celic.
Distribution The volume of distribution of free aflibercept at steady-state is approximately 8 litres.
Porazdelitev Volumen porazdelitve prostega aflibercepta v stanju dinamičnega ravnovesja je približno 8 litrov.
Your doctor will temporarily stop the treatment before and after surgery.
Zdravnik bo pred operacijo in po njej začasno prekinil vaše zdravljenje.
• Based on the required dose for the patient, withdraw the necessary volume of ZALTRAP concentrate from the vial.
• Glede na odmerek, ki ga potrebuje bolnik, izvlecite iz viale potrebno količino koncentrata zdravila ZALTRAP.
Reproductive and developmental toxicology
Reprodukcijska in razvojna toksikologija
This may include swelling of the feet or whole body and may be related to kidney disease.
Povezano je lahko z oteklostjo stopal ali vsega telesa in je lahko v zvezi z boleznijo ledvic.
Your doctor may need to treat you with other medicines and/or fluids given intravenously.
Zdravnik vas bo morda moral zdraviti z drugimi zdravili in/ali intravenskim dajanjem tekočine.